These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35116106)

  • 1. Statin as a therapeutic agent in gastroenterological cancer.
    Uemura N; Hayashi H; Baba H
    World J Gastrointest Oncol; 2022 Jan; 14(1):110-123. PubMed ID: 35116106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins as Anticancer Agents in the Era of Precision Medicine.
    Longo J; van Leeuwen JE; Elbaz M; Branchard E; Penn LZ
    Clin Cancer Res; 2020 Nov; 26(22):5791-5800. PubMed ID: 32887721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
    Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
    Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins inhibit blastocyst formation by preventing geranylgeranylation.
    Alarcon VB; Marikawa Y
    Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
    Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
    Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl-CoA reductase by mevalonate in Chinese hamster ovary cells. Magnitude and specificity.
    Panini SR; Schnitzer-Polokoff R; Spencer TA; Sinensky M
    J Biol Chem; 1989 Jul; 264(19):11044-52. PubMed ID: 2567731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins and cancer.
    Vallianou NG; Kostantinou A; Kougias M; Kazazis C
    Anticancer Agents Med Chem; 2014 Jun; 14(5):706-12. PubMed ID: 24295174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms.
    Fatehi Hassanabad A
    Transl Lung Cancer Res; 2019 Oct; 8(5):692-699. PubMed ID: 31737505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.
    Kim G; Kang ES
    Semin Liver Dis; 2019 May; 39(2):141-152. PubMed ID: 30912095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
    Perchellet JP; Perchellet EM; Crow KR; Buszek KR; Brown N; Ellappan S; Gao G; Luo D; Minatoya M; Lushington GH
    Int J Mol Med; 2009 Nov; 24(5):633-43. PubMed ID: 19787197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
    Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
    BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
    Mo H; Elson CE
    Exp Biol Med (Maywood); 2004 Jul; 229(7):567-85. PubMed ID: 15229351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin as Repurposed Drug in Ovarian Cancer: A Comprehensive Review.
    Ahmad A; Javed S; Kiran S
    Curr Pharm Des; 2023; 29(27):2116-2123. PubMed ID: 37711112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel applications of statins for bone regeneration.
    Shah SR; Werlang CA; Kasper FK; Mikos AG
    Natl Sci Rev; 2015 Mar; 2(1):85-99. PubMed ID: 26543666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins as potential therapeutic agents in multiple sclerosis.
    Stüve O; Prod'homme T; Youssef S; Dunn S; Neuhaus O; Weber M; Hartung HP; Steinman L; Zamvil SS
    Curr Neurol Neurosci Rep; 2004 May; 4(3):237-44. PubMed ID: 15102350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic use of Statins as non-lipid-lowering drugs.
    Zhang Q; Dong J; Yu Z
    Int J Biol Sci; 2020; 16(14):2704-2711. PubMed ID: 33110390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant p53, the Mevalonate Pathway and the Tumor Microenvironment Regulate Tumor Response to Statin Therapy.
    Pereira M; Matuszewska K; Glogova A; Petrik J
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-atherosclerotic actions of HMG-CoA reductase inhibitors].
    Gmiński J; Wojakowski W
    Przegl Lek; 1997; 54(11):782-7. PubMed ID: 9501689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.